#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Laryngeal squamous cell carcinoma Hereditary ataxia Leukaemia Acute graft versus host disease Chronic lymphocytic leukaemia recurrent Cerebellar ataxia Neuromyelitis optica spectrum disorder Myxofibrosarcoma Exudative retinopathy Autoimmune demyelinating disease Squamous cell carcinoma of the vulva IPEX syndrome Alagille syndrome Depression Inclusion body myositis More trials…

    Learn about Rare Diseases

    Medulloblastoma recurrent – Basic Information Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Diagnostics Systemic mastocytosis – Diagnostics Undifferentiated sarcoma – Diagnostics Rhabdoid tumour Mantle cell lymphoma stage III – Diagnostics Mucous membrane pemphigoid Hairy cell leukaemia recurrent – Diagnostics Richter’s syndrome – Treatment Phenylketonuria More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxycodone Hydrochloride Isotretinoin Tanimilast Disodium Levofolinate Aavanc80-3'Hotof Propranolol Hydrochloride Eribulin Reparixin SILYMARIN Danicamtiv Bevacizumab Dornase Alfa Eltrombopag Cx-044933 Exemestane Clonidine Hydrochloride Imiquimod Fosamprenavir Calcium S-241656 Navitoclax More therapies…

    Learn about Your Condition

    Cholangitis sclerosing Lung disorder Postoperative delirium Transitional cell carcinoma Univentricular heart Affective disorder Myocardial ischaemia Acute kidney injury Peritoneal dialysis Epilepsy Colorectal adenoma Antisynthetase syndrome Autoimmune haemolytic anaemia Hypotransferrinaemia Mucous membrane pemphigoid More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hereditary angioedema with C1 esterase inhibitor deficiency

  • A study of navenibart for long-term safety in patients with hereditary angioedema

    Recruiting

    3 1
    Investigated Diseases:
    • Hereditary angioedema
    • Hereditary angioedema with C1 esterase inhibitor deficiency
    Investigated Drugs:
    • NAVENIBART
    Austria Bulgaria Czechia France Germany Hungary +5

  • Study on C1 Esterase Inhibitor for Treating and Preventing Hereditary Angioedema Attacks in Patients with C1-INH Deficiency

    Recruiting

    3 1 1
    Investigated Drugs:
    • C1 Esterase Inhibitor (Human)
    • Sodium Chloride
    Bulgaria Romania

  • Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

    Recruiting

    4 1 1
    Investigated Diseases:
    • Hereditary angioedema with C1 esterase inhibitor deficiency
    Investigated Drugs:
    • (S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide
    • Icatibant
    • Deucrictibant
    Austria Bulgaria Czechia France Germany Hungary +8

  • Study of Navenibart to prevent attacks in adults and adolescents with Hereditary Angioedema

    Not recruiting

    3 1
    Investigated Diseases:
    • Hereditary angioedema with C1 esterase inhibitor deficiency
    • Hereditary angioedema
    Investigated Drugs:
    • NAVENIBART
    Austria Bulgaria Czechia France Germany Hungary +5

  • Study on the Safety and Effects of Sebetralstat for Children Aged 2-11 with Hereditary Angioedema Type I or II

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hereditary angioedema with C1 esterase inhibitor deficiency
    Investigated Drugs:
    • Sebetralstat
    France Germany Italy

  • Study on the Long-Term Safety of STAR-0215 for Adults with Hereditary Angioedema

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hereditary angioedema
    • Hereditary angioedema with C1 esterase inhibitor deficiency
    Investigated Drugs:
    • NAVENIBART
    Bulgaria Czechia Germany Poland
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!